Correlación del reemplazo percutáneo con cirugía aórtica convencional en pacientes con estenosis aórtica grave
Fecha
2019
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
La fibrilación auricular (FA) es la arritmia cardiaca más frecuente en la práctica clínica diaria. Los pacientes que reciben anticoagulantes orales como la warfarina tienen un mayor riesgo de sangrado y de eventos cardioembólicos que requiere una evaluación de riesgo individualizada. Una estratificación del riesgo de hemorragia personalizada es importante para planificar las medidas preventivas. Objetivo: Determinar el riesgo cardioembólico y hemorrágico con warfarina en fibrilación auricular valvular y no valvular en pacientes del hospital de especialidades Teodoro Maldonado Carbo durante el periodo del 2015 al 2017. Metodología: El estudio es tipo observacional, analítico, de corte transversal, que incluyó a 118 pacientes con fibrilación auricular del hospital captado desde el periodo del 1 de enero del 2015 hasta el 31 de diciembre del 2017. La gestión de datos se realizó en hojas de cálculo de Microsoft Excel 2010, donde se realizó el procesamiento de datos y para el análisis estadístico se empleó el programa SPSS versión 21. Resultados: En el grupo con warfarina, se observa mayor frecuencia de riesgo cardioembólico alto en los pacientes con FA no valvular (83,1%) vs los 78,7% del grupo con FA valvular. En el grupo con warfarina, se observa mayor frecuencia de riesgo alto de hemorragia en los pacientes con FA no valvular (43,7%) vs los 29,8% del grupo con FA valvular. Hubo 35 pacientes (29,7%) con complicaciones cardioembólicas y 29 pacientes con complicaciones hemorrágicas (25%), siendo la más frecuente la de tipo digestivo (15 casos). Conclusiones: Existe mayor riesgo cardioembólico y de hemorragia con el uso de warfarina en los pacientes con FA no valvular.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in daily clinical practice. Patients receiving oral anticoagulants such as warfarin have an increased risk of bleeding and cardioembolic events that requires an individualized risk assessment. A stratification of the risk of personalized hemorrhage is important to plan preventive measures. Objective: To determine the cardioembolic and hemorrhagic risk with warfarin in valvular and non-valvular atrial fibrillation in patients of the Teodoro Maldonado Carbo specialty hospital during the period from 2015 to 2017. Methodology: The study is an observational, analytical, cross-sectional type that included to 118 patients with atrial fibrillation from the hospital from the period of January 1, 2015 to December 31, 2017. Data management was performed in Microsoft Excel 2010 spreadsheets, where data processing was performed and for the statistical analysis was used the SPSS program version 21. Results: In the warfarin group, a higher frequency of high cardioembolic risk was observed in patients with non-valvular AF (83.1%) vs 78.7% in the group with valvular AF. In the group with warfarin, a higher frequency of high risk of bleeding was observed in patients with non-valvular AF (43.7%) vs 29.8% in the group with valvular AF. There were 35 patients (29.7%) with cardioembolic complications and 29 patients with hemorrhagic complications (25%), the most frequent being the digestive type (15 cases). Conclusions: There is an increased cardioembolic and hemorrhagic risk with the use of warfarin in patients with non-valvular AF.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in daily clinical practice. Patients receiving oral anticoagulants such as warfarin have an increased risk of bleeding and cardioembolic events that requires an individualized risk assessment. A stratification of the risk of personalized hemorrhage is important to plan preventive measures. Objective: To determine the cardioembolic and hemorrhagic risk with warfarin in valvular and non-valvular atrial fibrillation in patients of the Teodoro Maldonado Carbo specialty hospital during the period from 2015 to 2017. Methodology: The study is an observational, analytical, cross-sectional type that included to 118 patients with atrial fibrillation from the hospital from the period of January 1, 2015 to December 31, 2017. Data management was performed in Microsoft Excel 2010 spreadsheets, where data processing was performed and for the statistical analysis was used the SPSS program version 21. Results: In the warfarin group, a higher frequency of high cardioembolic risk was observed in patients with non-valvular AF (83.1%) vs 78.7% in the group with valvular AF. In the group with warfarin, a higher frequency of high risk of bleeding was observed in patients with non-valvular AF (43.7%) vs 29.8% in the group with valvular AF. There were 35 patients (29.7%) with cardioembolic complications and 29 patients with hemorrhagic complications (25%), the most frequent being the digestive type (15 cases). Conclusions: There is an increased cardioembolic and hemorrhagic risk with the use of warfarin in patients with non-valvular AF.
Descripción
PDF
Palabras clave
FIBRILACION AURICULAR, COMPLICACIONES, HEMORRAGIA, CARDIOLOGIA, HOSPITAL DE ESPECIALIDADES DR. TEODORO MALDONADO CARBO, CANTON GUAYAQUIL, ECUADOR